Trial · NCT00374322
Results by group488
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 488
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS]) | Lapatinib 1500 mg | Any recurrence or death | 252 | Participants | |
| Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS]) | Placebo | Any recurrence or death | 290 | Participants | |
| Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS]) | Lapatinib 1500 mg | Censored, New Anti-cancer Agent/Radiotherapy | 1 | Participants | |
| Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS]) | Placebo | Censored, New Anti-cancer Agent/Radiotherapy | 1 | Participants | |
| Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS]) | Lapatinib 1500 mg | Censored, Follow-up Ended | 1318 | Participants | |
| Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS]) | Placebo | Censored, Follow-up Ended | 1285 | Participants | |
| Number of Participants Who Died (Overall Survival) | Lapatinib 1500 mg | Died | 115 | Participants | |
| Number of Participants Who Died (Overall Survival) | Placebo | Died | 126 | Participants | |
| Number of Participants Who Died (Overall Survival) | Lapatinib 1500 mg | Censored, Follow-up Ended | 1456 | Participants | |
| Number of Participants Who Died (Overall Survival) | Placebo | Censored, Follow-up Ended | 1450 | Participants | |
| Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) | Lapatinib 1500 mg | 6 Months | 1.3 | Percentage of participants | |
| Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) | Placebo | 6 Months | 2.8 | Percentage of participants | |
| Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) | Lapatinib 1500 mg | 1Year | 3.7 | Percentage of participants | |
| Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) | Placebo | 1Year | 5.4 | Percentage of participants | |
| Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) | Lapatinib 1500 mg | 18 Months | 5.6 | Percentage of participants | |
| Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) | Placebo | 18 Months | 8.2 | Percentage of participants | |
| Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) | Lapatinib 1500 mg | 2 Years | 7.7 | Percentage of participants | |
| Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) | Placebo | 2 Years | 9.9 | Percentage of participants | |
| Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) | Lapatinib 1500 mg | 3 Years | 10.6 | Percentage of participants | |
| Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence) | Placebo | 3 Years | 12.6 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00374322/results